Research map: Venetoclax, azacitidine, and G-CSF targeting molecular residual disease in CBFB::MYH11 AML resistant to high-dose cytarabine

Back to the article

Papers in this map

  1. Selective BCL-2 Inhibition by ABT-199 Causes On-Target Cell Death in Acute Myeloid Leukemia · Rongqing Aaron Pan · 2013 · 754 citations · Cited by this paper
  2. Long-term follow-up of the transplant-eligible cohort of the EMN12/HOVON-129 study for primary plasma cell leukemia patients · 2026 · Related
  3. Induction of cell cycle entry eliminates human leukemia stem cells in a mouse model of AML · Yoriko Saito · 2010 · 423 citations · Cited by this paper
  4. Prospective phase II study of frontline Helicobacter pylori eradication therapy for early-stage extragastric mucosa-associated lymphoid tissue lymphoma · 2026 · Related
  5. Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia · Éric Jourdan · 2013 · 365 citations · Cited by this paper
  6. Fixed-dose inotuzumab ozogamicin (INO) combined with Vincristine and Prednisone (VP) regimen as induction therapy for newly diagnosed B-cell acute lymphocytic leukemia (B-ALL): a multi-center, open-label, single-arm, prospective clinical study · 2026 · Related
  7. MRD-directed risk stratification treatment may improve outcomes of t(8;21) AML in the first complete remission: results from the AML05 multicenter trial · Hong‐Hu Zhu · 2013 · 329 citations · Cited by this paper
  8. Linvoseltamab outcomes by frailty status in patients with relapsed/refractory multiple myeloma: a subgroup analysis of the LINKER-MM1 study · 2026 · Related
  9. Core binding factor acute myelogenous leukemia-2021 treatment algorithm · Gautam M. Borthakur · 2021 · 136 citations · Cited by this paper
  10. Response profile and long-term outcomes in Cyclin D1-overexpressing multiple myeloma: insights from the CASSIOPEIA trial · 2026 · Related
  11. Minimal residual disease eradication with epigenetic therapy in core binding factor acute myeloid leukemia · Brittany Knick Ragon · 2017 · 51 citations · Cited by this paper
  12. Preclinical and clinical efficacy of the HDAC6 inhibitor ricolinostat in combination with BCR pathway inhibitors in relapsed/refractory chronic lymphocytic leukemia · 2026 · Related
  13. Deregulated apoptosis signaling in core-binding factor leukemia differentiates clinically relevant, molecular marker-independent subgroups · Sonja C Lück · 2011 · 33 citations · Cited by this paper
  14. Long-term clinical outcomes from the smart start trial: rituximab, lenalidomide and ibrutinib in patients with newly diagnosed large B-cell lymphoma · 2026 · Related
  15. Activity of decitabine as maintenance therapy in core binding factor acute myeloid leukemia · Jayastu Senapati · 2022 · 27 citations · Cited by this paper
  16. Outcomes of patients with relapsed or refractory classic Hodgkin lymphoma after frontline brentuximab vedotin · 2026 · Related
  17. Venetoclax and azacitidine for molecular relapse after intensive chemotherapy in NPM1 or CBF AML: a FILO study · Jules Higué · 2025 · 6 citations · Cited by this paper
  18. Arterial thrombosis and cancer: insights from observations in myeloproliferative neoplasms and CHIP · 2026 · Related
  19. CAG (cytarabine, aclarubicin and granulocyte colony-stimulating factor) regimen for core binding factor acute myeloid leukaemia with measurable residual disease · Yaojia Shen · 2023 · 3 citations · Cited by this paper
  20. The efficacy, safety, and rationale of orelabrutinib combined with obinutuzumab (O2) as a first-line systemic treatment for marginal zone lymphoma · 2026 · Related
  21. Granulocyte colony-stimulating factor plus venetoclax and azacitidine in newly diagnosed acute myeloid leukemia: a multicenter phase 2 trial · Huaiyu Wang · 2025 · 2 citations · Cited by this paper
  22. Vag regimen drives immune reprogramming and superior remission in older/unfit AML patients · Yingying Huo · 2025 · 2 citations · Cited by this paper
  23. Co-Analysis of Genome-Wide DNA Methylation and Gene Expression Suggests Novel Regulatory Mechanism for RUNX1 in Inv(16) Acute Myeloid Leukemia · Ana Catarina Menezes · 2023 · 1 citation · Cited by this paper
  24. Untitled · Cited by this paper

Source: OpenAlex (CC0)